



Freedom of Information Team  
De La Court House  
Queen Alexandra Hospital  
Southwick Hill Road  
Portsmouth  
Hampshire  
PO6 3LY

Name:  
Email:  
Date: 16/06/2023  
Ref: 23-24 104

Dear

**RE: Freedom of Information request**

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 19/05/2023. Please see responses to your requests below.

**Question 1 - Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?**

Yes.

**Question 2 - How many patients were treated for endometrial cancer in the past 6 months with the following treatments:**

Please see below table.

<b>Systemic Anti-Cancer Therapy Regimen</b>	<b>Patients Treated</b>
Dostarlimab	<5
Hormone therapy (Progesterone or Letrozole)	0
Pembrolizumab monotherapy	0
Pembrolizumab in combination with Lenvatinib	0
Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)	13
Any other SACT	6

We are unable to provide precise figures when these are five or less due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure.

**Question 3 - How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:**

**Hormone therapy (Progesterone or Letrozole)**

In the past 6 months total of 8 patients have received Hormone therapy with our trust.

**Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)**

Not applicable, this is not recorded within the SACT data set.

**Any other SACT** – All SACT there are 5.

**Question 4 - Of the patients treated for endometrial cancer in the past 6 months with any SACT regimen, how many patients had high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)?**

Not applicable, this is not recorded within the SACT data set.

**Question 5 - Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.**

The trust currently has below clinical trials for the treatment of endometrial cancer.

PROTEC 3 – zero participants.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on [Information.Governance@porthosp.nhs.uk](mailto:Information.Governance@porthosp.nhs.uk) or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team